Health Condition 1: null- Lymphatic filariasis Microfilaria carriers
Conditions
Interventions
Intervention1: DEC+Albendazole co-administration: DEC 300 mg and Albendazole 400 mg per day given orally as single dose for 12 days,
Intervention2: DEC and Albendazole sequential administration: DEC
Sponsors
Indian Council of Medical Research
Vector Control Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: a) Age 18 years and above b) Residing in or around Pondicherry and adjoining Tamilnadu areas. c) with night blood microfilaria counts > 10 mf/ml by membrane filtration. d) No history of treatment for filarial infection for the last two years at least. e) Willing for home visits by the staff of the center. f) Willing to give written informed consent
Exclusion criteria
Exclusion criteria: a) Body weight less than 30 kg. b) Hepatic or renal disease as evidenced by clinical or biochemical abnormalities. c) concurrent illness like hypertension, diabetes mellitus, cardiac conditions and epilepsy requiring chronic medication. d) Psychiatric illness e). Patients under tetracycline or doxycycline therapy or History of de-worming by albendazole or other anti-helminthics during last one year, f). Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete clearance of mf in 80% of the participantsTimepoint: At 13th week (91 days) post therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete clearance Mf and complete clearance of antigen from the infectedTimepoint: a)Complete clearance of Mf by 26 weeks (180 days) post therapy. b) Complete clearance of antigen by 52 weeks (365days) post therapy | — |
Countries
India
Contacts
Public ContactMrs G Vijayalakshmi
Outcome results
None listed